Gilgamesh Pharmaceuticals has announced positive results from their Phase 1 trial of GM-2505, a novel 5-HT2A receptor agonist.

Cybin (NYSE: CYBN) has announced positive data from their Phase II clinical trial for their novel psilocybin analog CYB003.

Harvard University has received $16 million in new philanthropic funding to research psychedelic compounds for therapeutic potential.

Johnson and Johnson’s FDA approved esketamine nasal spray, known as Spravato, is showing more effectiveness on treatment resistant depression than traditionals.

Steve Cohen’s hedge fund Point 72, which boasts over $26 billion in assets, disclosed in a new filing they have purchased over 18M shares of Cybin (NYSE:CYBN)

The long awaited results from the MAPS Phase III clinical trial on MDMA as a therapeutic for PTSD have finally been announced.

While it’s still early, it is becoming clear that psychedelic medicine companies are entering into a new M&A era with traditional biotech majors.

COMPASS Pathways Secures $125M for Breakthrough Psychedelic Therapy: Advancing COMP360's Phase III FDA Trial. Major Investors Back Pioneering Treatment.

Johnson and Johnson's Spravato Sees Explosive Growth in Clinical Setting. Psychedelic Therapy Making Strides in Mental Healthcare.

The Rise and Fall of Psychedelic Medicine Companies in Public Markets. Despite Initial Challenges, Psychedelic Therapies Gain Momentum as Potential Game-Change